Didanosine-d2

Cat. No.:	HY-B0249S
Molecular Formula:	$C_{10}H_{10}D_2N_4O_3$
Molecular Weight:	238.24
Target:	Reverse Transcriptase; HIV; Isotope-Labeled Compounds
Pathway:	Anti-infection; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Didanosine-d_2 is the deuterium labeled Didanosine. Didanosine (Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Knupp, C.A., et al., Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther, 1991. 49(5): p. 523-35.

[3]. Bissuel, F., et al., Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med, 1994. 235(4): p. 367-71.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA